Angiology

Worldwide Vascular Endothelial Growth Factor Inhibitor Industry to 2030 - Players Include Regeneron Pharmaceuticals, Astrazeneca & Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 6, 2021
Health, Pharmaceutical, Branches of biology, Growth factors, Angiology, Vascular endothelial growth factor, Endothelium, Tyrosine kinase inhibitors, Angiogenesis inhibitor, VPF

Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

Key Points: 
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • The top opportunities in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type will arise in the tecentriq segment, which will gain $4,596.9 million of global annual sales by 2025.
  • The vascular endothelial growth factor (VEGF) inhibitor market size will gain the most in the USA at $7,015.6 million.

Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 in DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • THR-687 is a pan-RGD integrin inhibitor that is initially being developed as a potential first line therapy for DME patients.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

OXURION to Participate in Upcoming Investor Meetings

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Angiology, Clinical medicine, Medicine, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor, Euronext

The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.

Key Points: 
  • The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • THR-687 is a pan-RGD integrin inhibitor that is initially being developed as a potential first line therapy for all DME patients.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Physicians In The U.S. Begin Commercial Use Of The GORE® EXCLUDER® Conformable AAA Endoprosthesis With ACTIVE CONTROL System

Retrieved on: 
Tuesday, March 30, 2021
Medical specialties, Angiology, Vascular surgery, Cardiovascular system, Aortic aneurysm, Abdominal aortic aneurysm, Aneurysm, Gore, Clinical trial

FLAGSTAFF,Ariz., March 30, 2021 /PRNewswire/ --Today, W.L.Gore& Associates, Inc. (Gore) announces the first use of the FDA approved GORE EXCLUDERConformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials.

Key Points: 
  • FLAGSTAFF,Ariz., March 30, 2021 /PRNewswire/ --Today, W.L.Gore& Associates, Inc. (Gore) announces the first use of the FDA approved GORE EXCLUDERConformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials.
  • "Gore has combined a novel stent design, device conformability and an enhanced delivery system to give physicians even more control when we need it most."
  • For more information on the GORE EXCLUDER Conformable AAA Endoprosthesis and the GORE EXCLUDER Device family, visit goremedical.com .
  • Assessment of the GORE EXCLUDER Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms.

Therapeutic Solutions International Demonstrates Potent and Selective Destruction of Tumor Blood Vessels by Leveraging Pre-Existing Natural Anti-Xenogeneic Antibodies

Retrieved on: 
Monday, March 29, 2021
Medical specialties, Branches of biology, Clinical medicine, Immunology, Angiogenesis, Angiology, Immunotherapy, Cancer, Angiogenin, Antibody

ELK CITY, Idaho, March 29, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data and a new patent filing demonstrating this new immunotherapy derived from inducible pluripotent stem cells (iPSC) induces potent and selective killing of cancer associated blood vessels.

Key Points: 
  • ELK CITY, Idaho, March 29, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data and a new patent filing demonstrating this new immunotherapy derived from inducible pluripotent stem cells (iPSC) induces potent and selective killing of cancer associated blood vessels.
  • This is God's way of stopping inter-species transplantation.By directing this potent antibody response against tumor blood vessels our preliminary data supports feasibility of this novel approach in attacking the Achilles heel of cancer, which is angiogenesis."
  • "I commend our collaborating scientists for the completely novel concept of leveraging existing premade antibodies as a new way of shutting down the formation of new blood vessels by the cancer."
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

USA Vein Clinics Now Offers State-of-the-Art VenaSeal™ Closure Treatment for Varicose Veins

Retrieved on: 
Wednesday, March 24, 2021
Vascular surgery, Medical specialties, Angiology, Clinical medicine, Varicose veins, Perforator vein

NORTHBROOK, Ill., March 24, 2021 /PRNewswire-PRWeb/ -- USA Vein Clinics, a national network of minimally invasive vein treatment clinics, is now offering the VenaSeal Closure System for varicose veins.

Key Points: 
  • NORTHBROOK, Ill., March 24, 2021 /PRNewswire-PRWeb/ -- USA Vein Clinics, a national network of minimally invasive vein treatment clinics, is now offering the VenaSeal Closure System for varicose veins.
  • This state-of-the-art, non-surgical treatment is the latest in a range of office-based procedures performed by USA Vein Clinics' highly-trained vein treatment specialists.
  • "The VenaSeal closure system provides immediate vein closure, which allows for quick relief from painful and uncomfortable varicose vein symptoms like leg swelling, fatigue, itching, and cramping," said Yan Katsnelson, M.D., Founder and CEO, USA Vein Clinics.
  • USA Vein Clinics is the largest network of vein treatment centers in the United States with over 90 clinics.

Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood Vessels

Retrieved on: 
Tuesday, March 23, 2021
Medical specialties, Angiology, Clinical medicine, Medicine, Oncology, Immune system, Cancer, Blood vessel, Biotechnology, The Hallmarks of Cancer, Cancer vaccine

ELK CITY, Idaho, March 23, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent with new data on a unique cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels.

Key Points: 
  • ELK CITY, Idaho, March 23, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent with new data on a unique cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels.
  • Proof of selective killing of cancer blood vessels was obtained by demonstration of immune response to proteins found only on cancer blood vessels.
  • "By selectively killing cancer blood vessels the problem of mutations is solved since cancer blood vessels are not generated from tumor tissue and they do not mutate.
  • Furthermore, since blood vessels are in direct contact with the blood and immune cells that travel through the blood, it is substantially easier for the immune system to kill malignant vessels as opposed to tumors."

Nationally Recognized Leader in Vein Disease Treatment Commemorates DVT Awareness Month

Retrieved on: 
Tuesday, March 23, 2021
Medical specialties, Hematology, Angiology, Clinical medicine, Deep vein thrombosis, Venous thrombosis, Thrombosis, Deep vein, Post-thrombotic syndrome

23, 2021 /PRNewswire-PRWeb/ -- Throughout March 2021, Center for Vein Restoration (CVR) will again participate in national Deep Vein Thrombosis (DVT) Awareness Month.

Key Points: 
  • 23, 2021 /PRNewswire-PRWeb/ -- Throughout March 2021, Center for Vein Restoration (CVR) will again participate in national Deep Vein Thrombosis (DVT) Awareness Month.
  • CVR can also provide an immediate treatment plan for the DVT, or additional screening for vein disease, if needed.
  • March is officially recognized as Deep-Vein Thrombosis (DVT) Awareness Month by United States Senate Resolution 56.
  • ABOUT CENTER FOR VEIN RESTORATION Center for Vein Restoration (CVR) is the largest physician-led practice treating vein disease in the country.

SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche

Retrieved on: 
Monday, March 22, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Technology, Other Technology, Organ systems, Angiology, Diabetes, Vision, Medical specialties, Retinopathy, Diabetic retinopathy, Retina, Angiogenesis

SemaThera Inc. today announced the signing of a multi-year research collaboration and licensing agreement with Roche.

Key Points: 
  • SemaThera Inc. today announced the signing of a multi-year research collaboration and licensing agreement with Roche.
  • The partnership will focus on developing SemaTheras promising new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.
  • SemaThera holds exclusive rights to various technologies where Semaphorin 3A is involved in neo-angiogenesis, senescence and neuronal regeneration.
  • SemaThera has benefited from the financial support of the fund and of its Japanese partner Senju Pharmaceutical Co., LTD.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210322005164/en/

Author Kathleen Sargent's newly released "From My Heart to Your Heart" is an inspirational guide to understanding and working with emotions

Retrieved on: 
Monday, March 22, 2021
Angiology, Circulatory system, Exercise physiology, Heart

MEADVILLE, Pa., March 22, 2021 /PRNewswire-PRWeb/ -- "From My Heart to Your Heart": a wise, biblically inspired guide to personal freedom.

Key Points: 
  • MEADVILLE, Pa., March 22, 2021 /PRNewswire-PRWeb/ -- "From My Heart to Your Heart": a wise, biblically inspired guide to personal freedom.
  • "From My Heart to Your Heart" is the creation of published author, Kathleen Sargent, the founder and administrator of Prophetic Advancement Ministries and A Refuge in the City.
  • Sargent writes: "The natural heart is at the center of the circulatory system that pumps blood to your body.
  • This book, From My Heart to Your Heart, is the book that will help keep the emotional part of our heart in good working order.